- Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease dealHaving set Metsera on its journey to a $10 billion takeover, Arch Venture Partners and Population Health Partners have powered their new startup—Sentivera—to a licensing deal worth up to $1.5 billion.Fierce Biotech · 5h ago↗ source
- Merck and Moderna report positive topline results for personalized cancer vaccineA third death was reported in China’s expedited clinical trials, raising safety concerns for fast‑track studies in the region. Merck and Moderna announced positive topline data from their personal…